Ways2Capital Reviews : Natco/Mylan Gain Market Share In gCopaxone

Natco’s commercial partner Mylan has gained 18% market share in gCopaxone. The multiple sclerosis drug was launched by Mylan in Q3FY18 and is currently enjoying shared exclusivity in the drug with Sandoz.

As we had already mentioned, Dr Reddy's gCopaxone is delayed by about a year and Dr. Reddy’s is expecting to launch gCopaxone in the US market in H1FY20E.

While Teva, Copaxone’s innovator is trying to protect its market share, Natco/Mylan have gained 18.2% market share in 40mg and 4.8% market share in 20mg by end of May 2018.

In the 40mg/20mg, Mylan’s market share has gained by 150bps/110bps from March 2018.

In the 40mg, Sandoz’s gCopaxone (another generic product) is yet to show meaningful market share, while in 20mg Sandoz’s gCopaxone has started to show meaningful decline in the market share.

This is expected to be positive for Natco, which is expected to reap huge profits in FY19E and FY20E. Natco in Q4FY18 conference call has also said that it will see slow ramp-up of its market share in gCopaxone going ahead. 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai